SILO Silo Pharma, Inc.
Healthcare$0.41+5.12%ClosedMarket Cap: $3.3M
As of 2026-05-26
Valuation
P/E (TTM)
—
PEG
—
P/B
0.94
P/S
43.44
EV/EBITDA
0.16
DCF Value
$0.43
FCF Yield
-122.7%
Div Yield
0.0%
Margins & Returns
Gross Margin
-328.7%
Operating Margin
-6631.2%
Net Margin
-6717.4%
ROE
-88.4%
ROA
-69.0%
ROIC
-75.7%
Income Statement
Periods shown are fiscal year quarters (may differ from calendar year)
| Period | Revenue | Gross Margin | Operating Income | Net Income | EPS | Dividend |
|---|---|---|---|---|---|---|
| Q1 null | $18.0K | -1377.1% | $-1.6M | $-1.6M | $— | — |
| Q4 null | $18.0K | -14.8% | $-786.5K | $-881.5K | $— | — |
| FY null | $72.1K | -1128.9% | $-4.3M | $-4.2M | $— | — |
| Q3 null | $18.0K | -14.8% | $-1.2M | $-1.1M | $— | — |
| Q2 null | $18.0K | 91.9% | $-1.2M | $-1.2M | $— | — |
| Q1 null | $18.0K | 91.9% | $-1.1M | $-1.0M | $— | — |
| Q4 null | $18.0K | -2118.3% | $-1.9M | $-1.7M | $— | — |
| FY null | $72.1K | 91.9% | $-4.7M | $-4.4M | $— | — |
| Q3 null | $18.0K | 91.9% | $-1.0M | $-928.8K | $— | — |
| Q2 null | $18.0K | 91.9% | $-1.0M | $-931.8K | $— | — |
| Q1 null | $18.0K | 91.9% | $-879.5K | $-801.7K | $— | — |
| Q4 2023 | $18.0K | 91.9% | $-1.2M | $-1.1M | $-0.39 | — |